COSMOS-DIGITAL

Completed

A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss

Community Outreach Support and Engagement Using Online Strategies - Decentralized Insights Into Therapy Adoption and Value

Lead sponsor

Amgen

Assets

Semaglutide / Tirzepatide

Listed sites

Recruiting sites

—

Enrollment

200

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Self-blood Draw Received by Central Laboratory

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06761703

Org study ID20240163

Timeline

Milestones

Study start2024-11-14actual

Primary completion2025-01-06actual

Study completion2025-01-06actual

Study first posted2025-01-07actual

Last update posted2025-01-14actual

Assets

Investigational agents

Semaglutide Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersAccepted

Sampling methodNon probability sample

Study population text

Adults using the anti-obesity medications, semaglutide and tirzepatide, indicated for weight loss.

Inclusion criteria

•Adults 18 - 80 years of age.

•Living in the United States.

•Consented from the Inspire online platform patient community for COSMOS-DIGITAL.

•Self-Reported current use of, and intention to continue for at least 30 days, one of the following medications for the indications of weight management/obesity:

•Semaglutide (wegovy)

•Tirzepatide (zepbound)

Exclusion criteria

•Currently receiving treatment in another investigational device or drug study, or participation in a current clinical trial.

•Self-reported sensitivity/allergy to any of the components of the self-draw collection device including stainless steel or elements commonly found in stainless steel.

•Self-reported fear of blood.

•Self-reported circulatory conditions causing difficulty in drawing capillary blood.

•Known history of bleeding diathesis or any coagulation disorder.

•History of skin disorders, abnormal skin integrity or atypical skin health within the areas to be tested in the upper arm.

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL

Safety / tolerability / PK

Other (unclassified)

Patient-reported / QoL

3 endpoints

Secondary/protocol endpoint

Percentage of Consented Participants with Complete Self-reported Survey for Patient Reported Outcomes in Obesity

Time frame:Day 1 and Day 30

descriptive

Secondary/protocol endpoint

Percentage of Consented Participants with Complete Self-reported Survey for Partners in Health (PiH) Questionnaire

Time frame:Day 1 and Day 30

descriptive

Secondary/protocol endpoint

Percentage of Consented Participants with Complete Self-reported Survey for the Satisfaction Survey

Time frame:Day 30

descriptive

Safety / tolerability / PK

3 endpoints

Secondary/protocol endpoint

Percentage of Consented Participants with Complete Self-reported Survey for Nausea and Nausea Management

Time frame:Day 1 and Day 30

descriptive

Secondary/protocol endpoint

Percentage of Consented Participants with Complete Self-reported Survey for the Daily Diary

Time frame:30 days

descriptive

Secondary/protocol endpoint

Percentage of Participants with Sufficient Volume of Blood Collected for Sampling

Time frame:30 days

descriptive

Other (unclassified)

2 endpoints

Primary/protocol endpoint

Number of Participants with Self-blood Draw Received by Central Laboratory

Time frame:30 days

descriptive

Secondary/protocol endpoint

Percentage of Consented Participants with Complete Self-reported Survey for Medical History

Time frame:Day 1

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.